NCT03357263View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 20, 2017

Primary Completion Date

December 22, 2017

Study Completion Date

December 22, 2017

Conditions
Influenza, Human
Interventions
BIOLOGICAL

GC3114

High-dose Quadrivalent influenza vaccine

BIOLOGICAL

GCFLU Quadrivalent

Quadrivalent influenza vaccine

Trial Locations (1)

Unknown

Korea University Guro Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Green Cross Corporation

INDUSTRY

NCT03357263 - A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Healthy Adults | Biotech Hunter | Biotech Hunter